FIELD: medicine.
SUBSTANCE: invention refers to medicine, and describes a method for testing a planned or known immunomodulatory agent for T-cell activation which involves the stage of contacting a peripheral blood mononuclear cell (PBMC) culture with the pre-determined amount of the planned or known immunomodulatory agent in vitro and observing the T-cell activation in the PBMC culture using a readout system, when contacting the planned or known immunomodulatory agent, wherein the PBMC culture density at the stage of pre-culture makes at least 2×106/ml, preferentially at least 5×106/ml, more preferentially at least 107/ml, or at least 4×105/cm2, preferentially at least 106/cm2, most preferentially at least 2×106/cm2; the PBMC pre-culture is cultured for at least 12 hours.
EFFECT: invention provides the improved agent for testing the immunomodulatory agents in vitro.
10 cl, 16 dwg, 13 ex
Title | Year | Author | Number |
---|---|---|---|
PHARMACEUTICAL PREPARATION | 2009 |
|
RU2542512C2 |
5-(4-METHANESULPHONYL PHENYL)THIAZOLE DERIVATIVES FOR TREATING ACUTE AND CHRONIC INFLAMMATORY DISEASES | 2009 |
|
RU2495031C2 |
IMPROVED METHODS FOR PRODUCING ADOPTIVE CELL THERAPY AGENTS | 2015 |
|
RU2741899C2 |
ANTIBODIES AGAINST αβTCR | 2012 |
|
RU2630656C2 |
METHOD OF ENHANCEMENT OF IMMUNE RESPONSE TO ANTIGENE IN MAMMALS | 2004 |
|
RU2341289C2 |
COMPOSITION FOR TREATING ARTHRITIS | 2009 |
|
RU2563360C2 |
METHOD OF TREATING AUTOIMMUNE DISEASE (VERSIONS) | 2009 |
|
RU2539110C2 |
AGENT FOR TREATING DISEASE | 2009 |
|
RU2540013C2 |
PROBIOTIC STRAIN OF Bifidobacterium longum, COMPOSITION CONTAINING SUCH STRAIN AND USE THEREOF | 2008 |
|
RU2473681C2 |
IMMUNOMODULATORY PROBIOTIC LACTIC-ACID BACTERIA | 2007 |
|
RU2535974C2 |
Authors
Dates
2014-06-20—Published
2010-09-28—Filed